The African-PREDICT Study

Hypertension Clinical Trial

— PREDICT  

Official title:

African Prospective Study for the Early Detection and Identification of Cardiovascular Disease and Hypertension (African-PREDICT Study)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03292094
• Other study ID #: NWU-00001-12-A1
• Status: Active, not recruiting
• Start date: February 4, 2013
• Est. completion date: December 3, 2027

Study information

• Verified date: April 2024
• Source: North-West University, South Africa
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The African-PREDICT study aims to (i) generate new knowledge on the early pathophysiology accompanying hypertension development in black South Africans; and (ii) to identify early novel markers or predictors for the development of hypertension and cardiovascular outcome. By employing also in Africa the latest cutting-edge scientific technologies to measure single and multiple biomarkers proven to predict hypertension and cardiovascular outcome (such as multiplex analyses, proteomics and metabolomics), precision medicine may have the potential to lead to novel strategies in preventing and treating hypertension in Africa.

Description:

Background and Problem Statement: Recent global analyses have indicated that the highest blood pressures worldwide are recorded in black populations. The vulnerable cardiovascular profile of Africans is believed to result from a combination of factors such as rapid urbanisation, abnormal sodium handling, elevated vascular resistance and arterial stiffness. The frequent underdiagnoses and ineffective treatment of hypertension in general but especially in Africans, result in severe complications, such as stroke, heart and kidney disease. Since diagnosis and treatment are generally unsuccessful in black populations - especially in low and middle-income countries - prevention is key to curb the rapidly increasing incidence of death and disability from cardiovascular disease. Cardiovascular risk prediction in black populations worldwide is inadequate since we do not have a clear understanding of the complex mechanisms underlying the development of cardiovascular disease.

Main Aim: In the "African PRospective study on the Early Detection and Identification of Cardiovascular disease and Hypertension" (African-PREDICT) the investigators aim to identify early markers or predictors for the development of cardiovascular disease in black South Africans. Only by understanding the early pathophysiology of disease development, and by identifying markers as potential screening indicators, predictors or targets for intervention, will the investigators be able to implement successful prevention programes in Africans at younger ages. The researchers therefore aim to track and monitor change in young, normotensive black and white individuals (aged 20-30 years) over 10-20 years. To achieve this the investigators will perform detailed cardiovascular and novel biomarker measurements, as well as behavioural and biopsychosocial assessments every 4-5 years in order to identify and understand early changes in cardiovascular function, and specific predictors contributing to the development of hypertension and target organ damage.

Methodology and Measurements: In 2013 recruitment started, screening and assessment of 1200 normotensive and apparently healthy participants (black N=600 and white N=600) with equal sex distribution. A wide range of basic and advanced measurements are taken within a Hypertension Clinic to get a highly detailed profile of the participants at each visit. The following is obtained: (1) relevant questionnaire data including medical history, lifestyle, social status, traditional risk factors (age, gender, smoking, alcohol intake) and validated questionnaires on dietary intake, personality and psychosocial profile; (2) Biological samples for biomarker analyses (serum, plasma, spot urine and 24-hr urine) are taken and preserved for the short and long-term at -80°C. A wide range of traditional and novel biomarkers related to hypertension and cardiovascular disease (including amongst others, lipid profile, glucose, glycated hemoglobin, C-reactive protein, interleukin-6, vitamin D, full blood count, sodium, potassium, creatinine, renin, aldosterone, angiotensin II, markers of oxidative stress and nitric oxide bio-availability, cortisol, sex hormones, insulin, C-peptide, leptin and other adipokines, angiogenic markers, the insulin-like growth factor-axis, soluble urokinase plasminogen activator receptor, Nt-proBNP, fibulin-1 and novel markers not yet identified) will be assessed. These samples will also be analysed in an attempt to identify bio-signatures in terms of the -omics sciences (genomic, metabolomic and proteomic profiles) as predictors of cardiovascular deterioration; (3) anthropometric measurements, bio-electrical impedance measurement of body fat and lean mass, and 7-day physical activitymonitoring; (4) A range of cardiovascular assessments: 24-hour blood pressure, central arterial pressure, and cardiovascular stress reactivity tests with continuous finger blood pressure; and (5) Assessments of early target organ damage including urinary albumin-to-creatinine ratio, carotid intima-media thickness, ECG, echocardiography, pulse wave velocity, and retinal microvascular calibre and dilation during provocation with a light flicker test.

Timetable: The project was approved and is endorsed by the National and Provincial Department of Health, and was approved by the Ethics Committee of the North-West University in 2012 (NWU-00001-12-A1). Screening commenced in November 2012, and research participants started entering the study from 6 February 2013. Baseline data collection was completed in December 2017. Follow-up assessments commenced in February 2018 and will continue until Dec 2022. The Health Research Ethics Committee approved continuation of the study for 2020.

Anticipated Outcomes: This project will increase understanding of the complex mechanisms involved in the aetiology of early cardiovascular changes in relatively young individuals from African and European ancestry, which will (1) improve ability to identify individuals at risk before the development of cardiovascular diseases (CVD), and (2) predict the development of future hypertension and related CVD. Both outcomes will make it possible to develop better individualised and population-based prevention of CVD contributing to better quality of life. These results will not only be applicable to Sub-Saharan Africa but are expected to have a broader impact with regards to white and black populations globally. Results are expected to have significant scientific impact by means of publications in high-impact journals; and also to translate directly into novel preventive healthcare policy and practices - translating into preventive measures regarding the development of CVDs in clinics throughout South Africa.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1202
• Est. completion date: December 3, 2027
• Est. primary completion date: November 30, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 30 Years

Eligibility

Inclusion Criteria:

• Brachial BP <140 and 90 mmHg

• HIV uninfected

• No previous diagnosis or medication for chronic disease

• Not pregnant or breastfeeding

Exclusion Criteria:

• Planning to move away from the Potchefstroom area in the next 5 years

• Currently pregnant or breastfeeding

• Sick on the day of appointment

• Lack the ability to read or understand English

• Diagnosed with HIV, Cancer, Tuberculosis, Diabetes, Hypertension, Liver or Kidney disease, Heart disease

• Previously had a heart attack or stroke

• Have suffered a recent trauma or had surgery in the past 3 months

• Have a phobia for needles

• Have donated blood in the previous 3 months

• Taking chronic medication (Anti-inflammatory, for Hypertension of Diabetes, Cortisone, Anti-Retroviral, Thyroid medication, Cholesterol medication)

Related Conditions & MeSH terms

• Arterial Stiffness
• Cardiovascular Diseases
• Health Risk Behaviors
• Hypertension
• Renin Hypertension
• Young

Locations

Country	Name	City	State
South Africa	Hypertension Research and Training Clinic	Potchefstroom	North West

Sponsors (10)

Lead Sponsor	Collaborator
North-West University, South Africa	Boehringer Ingelheim, GlaxoSmithKline, Medical Research Council, Medical Research Council, South Africa, Mediclinic Hospital, National Research Foundation of South Africa, Novartis, Pfizer, Roche Diagnostics

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incident Hypertension	Incident hypertension based on 4 repeated clinic blood pressure measurements, i.e. SBP>=140 mmHg and/or DBP >=90 mmHg.	5 years

External Links

•   Regular updates on publications